Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Mabs|March 5, 2024
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsSophie Tourdot, Daniel Baltrunkonis, Sofie Denies, et al.
The AAPS Journal|May 13, 2022
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity PlatformGregor P Lotz, Karin Benstein, Karien Bloem, et al.
Journal of Neuroimmunology|July 19, 2022
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysisLinda van der Weele, Sabrina Pollastro, Barbera D C van Schaik, et al.
Acta Biomaterialia|March 4, 2025
Quantifying physical degradation alongside recording and stimulation performance of 980 intracortical microelectrodes chronically implanted in three humans for 956-2130 daysDavid A Bjånes, Spencer Kellis, Robert Nickl, et al.
Frontiers in Immunology|June 6, 2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity PlatformJoanna Grudzinska-Goebel, Karin Benstein, Karien Bloem, et al.
Mabs|April 4, 2025
Proceedings of the 15th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsSophie Tourdot, Karien Bloem, Lysie Champion, et al.
The AAPS Journal|December 2, 2021
Anti-drug Antibody Validation Testing and Reporting HarmonizationHeather Myler, João Pedras-Vasconcelos, Kelli Phillips, et al.
Journal of Neuroimmunology|November 18, 2018
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort studyPoul Erik H Jensen, Clemens Warnke, Kathleen Ingenhoven, et al.
Bioanalysis|November 19, 2016
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity)Susan Richards, Lakshmi Amaravadi, Renuka Pillutla, et al.
Bioanalysis|January 25, 2025
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation (PART 3A - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance PART 3B - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)Omar Tounekti, Sandra Prior, Sarah Wassmer, et al.
Pageof 7